ALKS
Alkermes plc

2,164
Mkt Cap
$4.76B
Volume
1.6M
52W High
$36.45
52W Low
$25.17
PE Ratio
14.34
ALKS Fundamentals
Price
$28.99
Prev Close
$28.20
Open
$28.38
50D MA
$30.21
Beta
0.58
Avg. Volume
2.25M
EPS (Annual)
$2.17
P/B
2.76
Rev/Employee
$865,351.11
Loading...
Loading...
News
all
press releases
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesday, Dec. 3, 2025 at 2:10...
Business Wire·7h ago
News Placeholder
More News
News Placeholder
Alkermes plc $ALKS Stock Position Raised by Segall Bryant & Hamill LLC
Segall Bryant & Hamill LLC lifted its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 12.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The...
MarketBeat·2d ago
News Placeholder
Alkermes (NASDAQ:ALKS) Rating Lowered to Hold at Zacks Research
Zacks Research lowered shares of Alkermes from a "strong-buy" rating to a "hold" rating in a research report on Thursday...
MarketBeat·3d ago
News Placeholder
Neo Ivy Capital Management Invests $462,000 in Alkermes plc $ALKS
Neo Ivy Capital Management acquired a new position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange...
MarketBeat·3d ago
News Placeholder
FY2025 EPS Estimates for Alkermes Boosted by Zacks Research
Alkermes plc (NASDAQ:ALKS - Free Report) - Analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Alkermes in a research report issued to clients and investors on...
MarketBeat·4d ago
News Placeholder
Primecap Management Co. CA Decreases Stock Holdings in Alkermes plc $ALKS
Primecap Management Co. CA lowered its holdings in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 3.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·5d ago
News Placeholder
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
Zacks·5d ago
News Placeholder
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
Zacks·6d ago
News Placeholder
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
Zacks·7d ago
News Placeholder
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks TakeTwo Interactive Software (TTWO), Allstate (ALL), SoFi Technologies (SOFI), Alkermes (ALKS) and Morgan Stanley (MS) are likely to beat on the bottom line in their upcoming releases.
Zacks·7d ago

Latest ALKS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.